Currently, Immunome Inc [IMNM] is trading at $21.71, down -2.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMNM shares have gain 8.82% over the last week, with a monthly amount glided 18.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on December 01, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $36. Previously, Goldman started tracking the stock with Buy rating on September 22, 2025, and set its price target to $26. On September 05, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $26 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $23 on April 02, 2025. Stephens initiated its recommendation with an Overweight and recommended $30 as its price target on November 08, 2024. Piper Sandler started tracking with an Overweight rating for this stock on May 31, 2024, and assigned it a price target of $27. In a note dated April 30, 2024, JP Morgan initiated an Overweight rating and provided a target price of $24 on this stock.
This stock has fluctuated between a low of $5.15 and a high of $25.30 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $21.71 at the most recent close of the market. An investor can expect a potential return of 58.91% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Trailing Twelve Months sales for Immunome Inc [NASDAQ:IMNM] were 9.68M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.84%, Pretax Profit Margin comes in at -16.87%, and Net Profit Margin reading is -16.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.87 and Total Capital is -0.82. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.31 points at the first support level, and at 20.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.14, and for the 2nd resistance point, it is at 22.56.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunome Inc [NASDAQ:IMNM] is 8.90. Also, the Quick Ratio is 8.90, while the Cash Ratio stands at 6.29. Considering the valuation of this stock, the price to sales ratio is 247.46, the price to book ratio is 7.54.
Transactions by insiders
Recent insider trading involved Barchas Isaac, Director, that happened on Dec 22 ’25 when 0.38 million shares were sold. President and CEO, SIEGALL CLAY B completed a deal on Dec 19 ’25 to buy 7278.0 shares. Meanwhile, Chief Technical Officer Tsai Philip bought 10000.0 shares on Dec 19 ’25.
